Physician profile
David A Simpson
NPI 1912996265
$15,290.15
in general payments reported to CMS, 2019-2025
30 companies · $32.33 in 2025
The $32.33 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $92.66 · 2021: $431 · 2022: $12K · 2023: $1,149 · 2024: $827 · 2025: $32.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $10,544.23 | 2022 | |
| Biogen, INC. | $872.99 | 2021-2024 | Vumerity, Tysabri, Avonex |
| Amgen INC. | $565.53 | 2019-2022 | |
| Ucb, INC. | $445.87 | 2019-2024 | Briviact, Rystiggo, Fintepla |
| Avanir Pharmaceuticals, INC. | $385.62 | 2019-2022 | |
| Csl Behring | $324.90 | 2022-2024 | Hizentra |
| Novartis Pharmaceuticals Corporation | $316.86 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $307.12 | 2023 | Nuedexta |
| Alexion Pharmaceuticals, INC. | $272.00 | 2019-2024 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $223.48 | 2019-2025 | Austedo Xr |
| Allergan, INC. | $162.84 | 2019-2021 | |
| Lilly USA, LLC | $123.80 | 2022-2024 | Emgality, Reyvow |
| Sumitomo Pharma America, INC. | $111.35 | 2023-2024 | Aptiom |
| Sunovion Pharmaceuticals INC. | $104.04 | 2019-2020 | |
| Acorda Therapeutics, INC | $77.57 | 2019-2023 | Inbrija |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $64.83 | 2019-2020 | |
| Emd Serono, INC. | $49.51 | 2019 | |
| Alnylam Pharmaceuticals INC. | $48.47 | 2019 | |
| Neurocrine Biosciences, INC. | $46.44 | 2019-2022 | |
| Genentech USA, INC. | $38.53 | 2020-2024 | Enspryng, Ocrevus |
| Tg Therapeutics, INC. | $38.20 | 2023-2024 | |
| Livanova USA, INC. | $27.08 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $26.29 | 2022 | |
| Grifols USA, LLC | $20.24 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.50 | 2019 | |
| Abbvie INC. | $17.73 | 2024 | |
| Tanabe Pharma America, INC. | $16.44 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $14.80 | 2024 | |
| Pfizer INC. | $12.19 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.